{{Drugbox
| IUPAC_name = (3''S'',4a''S'',13b''S'')-3-(2-Methyl-2-propanyl)-2,3,4,4a,8,9,13b,14-octahydro-1''H''-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol
| image = Butaclamol.svg
| width = 222

<!--Clinical data-->
| tradename =

<!--Identifiers-->
| CAS_number = 36504-93-5
| PubChem = 37459
| IUPHAR_ligand = 62
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 73298
| ChemSpiderID = 34364
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A7A2802VNL
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 479587
| ATC_prefix = none

<!--Chemical data-->
| C=25 | H=31 | N=1 | O=1
| molecular_weight = 361.52 g/mol
| smiles = CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O
}}

'''Butaclamol''' ('''AY-23,028''') is a [[typical antipsychotic]] which was never marketed.<ref name="urlDictionary of organic compounds - Google Books">{{cite book | url = https://books.google.com/books?id=wZawOvjGME0C&lpg=PA1131&dq=butaclamol&pg=PA1131#v=onepage&q=&f=false | title = Dictionary of organic compounds - Google Books | format = | work = | accessdate = | isbn = 9780412540905 | author1 = Buckingham | first1 = J }}</ref> Sold as the hydrochloride salt for use in research, the compound acts as a [[dopamine receptor]] [[receptor antagonist|antagonist]].<ref> http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=D033%7CSIGMA&N25=0&QS=ON&F=SPEC </ref>

==Chemistry==
pK<sub>a</sub> = 7.15 (uncorrected for [[ionic strength]])<ref>F. A. Chrzanowski, B. A. McGrogan, B. E. Maryanoff (1985). "The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors." ''J. Med. Chem.'' '''28''' 399-400.</ref>

==References==
{{Reflist}}

{{Antipsychotics}}
{{Dopamine receptor modulators}}
{{Sigma receptor modulators}}
{{Tricyclics}}

[[Category:Abandoned drugs]]
[[Category:Alcohols]]
[[Category:Antipsychotics]]
[[Category:Dopamine antagonists]]
[[Category:Sigma receptor ligands]]

{{nervous-system-drug-stub}}